158 related articles for article (PubMed ID: 35088375)
1. Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.
Zargar P; Koochakkhani S; Hassanzadeh M; Ashouri Taziani Y; Nasrollahi H; Eftekhar E
Mol Biol Rep; 2022 Apr; 49(4):2755-2763. PubMed ID: 35088375
[TBL] [Abstract][Full Text] [Related]
2. Acriflavine enhances the antitumor activity of the chemotherapeutic drug 5-fluorouracil in colorectal cancer cells.
Zargar P; Ghani E; Mashayekhi FJ; Ramezani A; Eftekhar E
Oncol Lett; 2018 Jun; 15(6):10084-10090. PubMed ID: 29928378
[TBL] [Abstract][Full Text] [Related]
3. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
4. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
5. Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.
Lee A; Jin HO; Masudul Haque M; Kim HY; Jung H; Park JH; Kim I; Song JY; Yoon HK; Kim HK; Han J; Park IC; Kim KS; Park SG
Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34913076
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro.
Khodadadi F; Khorashadizadeh M; Ghasemi F
Mol Biol Rep; 2023 Jul; 50(7):5767-5775. PubMed ID: 37219672
[TBL] [Abstract][Full Text] [Related]
7. Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Lim MJ; Ahn JY; Han Y; Yu CH; Kim MH; Lee SL; Lim DS; Song JY
Int J Biochem Cell Biol; 2012 Aug; 44(8):1214-22. PubMed ID: 22564437
[TBL] [Abstract][Full Text] [Related]
8. Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells.
Hallal R; Nehme R; Brachet-Botineau M; Nehme A; Dakik H; Deynoux M; Dello Sbarba P; Levern Y; Zibara K; Gouilleux F; Mazurier F
J Cell Mol Med; 2020 Sep; 24(17):10052-10062. PubMed ID: 32667731
[TBL] [Abstract][Full Text] [Related]
9. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy.
Zhang X; He C; Liu X; Chen Y; Zhao P; Chen C; Yan R; Li M; Fan T; Altine B; Yang T; Lu Y; Lee RJ; Gai Y; Xiang G
Theranostics; 2020; 10(7):2918-2929. PubMed ID: 32194844
[TBL] [Abstract][Full Text] [Related]
10. The Activation of the Tumor Suppressor Protein p53 by Acriflavine Leads to Mitochondrial Dysfunction and Improves the Radiosensitivity of Colon Cancer Cells.
Lin C; Chen X; Qiu H; Li B; Guo M
J Immunol Res; 2022; 2022():1328542. PubMed ID: 35935580
[TBL] [Abstract][Full Text] [Related]
11. MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes.
Salimian J; Baradaran B; Azimzadeh Jamalkandi S; Moridikia A; Ahmadi A
Urol Oncol; 2020 Sep; 38(9):738.e9-738.e21. PubMed ID: 32527702
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
13. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
14. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
[TBL] [Abstract][Full Text] [Related]
15. The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer.
Chen X; Liu M; Meng F; Sun B; Jin X; Jia C
J Cell Biochem; 2019 Jan; 120(1):243-252. PubMed ID: 30216500
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
Lee CJ; Yue CH; Lin YJ; Lin YY; Kao SH; Liu JY; Chen YH
Anticancer Res; 2014 Nov; 34(11):6467-72. PubMed ID: 25368247
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
